- Home
- CANF vs NTRP Comparison
CANF vs NTRP Comparison
Compare CANF & NTRP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CANF
- NTRP
- Stock Information
- Founded
- CANF 1994
- NTRP 1985
- Country
- CANF Israel
- NTRP United States
- Employees
- CANF N/A
- NTRP N/A
- Industry
- CANF Biotechnology: Pharmaceutical Preparations
- NTRP
- Sector
- CANF Health Care
- NTRP
- Exchange
- CANF Nasdaq
- NTRP NYSE
- Market Cap
- CANF 14.8M
- NTRP 13.6M
- IPO Year
- CANF N/A
- NTRP N/A
- Fundamental
- Price
- CANF $1.05
- NTRP $2.27
- Analyst Decision
- CANF Strong Buy
- NTRP Hold
- Analyst Count
- CANF 2
- NTRP 1
- Target Price
- CANF $14.00
- NTRP $5.00
- AVG Volume (30 Days)
- CANF 172.6K
- NTRP 307.7K
- Earning Date
- CANF 05-27-2025
- NTRP 05-27-2025
- Dividend Yield
- CANF N/A
- NTRP N/A
- EPS Growth
- CANF N/A
- NTRP N/A
- EPS
- CANF N/A
- NTRP N/A
- Revenue
- CANF $674,000.00
- NTRP $623,664.00
- Revenue This Year
- CANF $461.72
- NTRP $354.28
- Revenue Next Year
- CANF N/A
- NTRP $536.37
- P/E Ratio
- CANF N/A
- NTRP N/A
- Revenue Growth
- CANF N/A
- NTRP 186.93
- 52 Week Low
- CANF $1.02
- NTRP $1.39
- 52 Week High
- CANF $4.69
- NTRP $8.50
- Technical
- Relative Strength Index (RSI)
- CANF 37.30
- NTRP 41.02
- Support Level
- CANF $0.98
- NTRP $2.04
- Resistance Level
- CANF $1.14
- NTRP $2.48
- Average True Range (ATR)
- CANF 0.06
- NTRP 0.45
- MACD
- CANF 0.01
- NTRP 0.11
- Stochastic Oscillator
- CANF 32.59
- NTRP 47.56
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).
About NTRP NEXTTRIP INC
NextTrip Inc is a technology-driven platform delivering travel booking and travel media solutions. It provides individual and group travelers with vacations to popular and sought-after destinations in Mexico, the Caribbean, and across the world. NextTrip Media platform - Travel Magazine offers a social media platform for viewers to explore, educate, and share with friends their bucket list travel. The company is also launching an end-to-end content ecosystem that uses AI-assisted travel planning capturing advertising, building brand awareness, rewarding loyalty, and driving bookings.